Literature DB >> 9431711

Topical diclofenac/hyaluronic acid gel in the treatment of solar keratoses.

L E McEwan1, J G Smith.   

Abstract

A randomized double-blind controlled trial of 130 patients was performed to study the efficacy and tolerability of topical 3% diclofenac in 2.5% hyaluronic acid (HA) gel (active) versus gel containing 2.5% HA alone (control) in the treatment of solar keratoses. Patients were asked to apply trial gel to the target lesion twice a day and also sunscreen once a day for 24 weeks. The complete response rates were 29% for the active gel and 17% for the control gel. The difference was not statistically significant (P = 0.14). A high percentage of patients in both groups experienced a partial response to treatment (38% active, 45% control) but there was no significant difference in the spectrum of response between the two treatments (P = 0.18). Local adverse reactions occurred significantly more frequently in patients using the active gel (29% compared to 5% using control gel, P = 0.0002).

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9431711     DOI: 10.1111/j.1440-0960.1997.tb01693.x

Source DB:  PubMed          Journal:  Australas J Dermatol        ISSN: 0004-8380            Impact factor:   2.875


  6 in total

1.  Nonsurgical innovations in the treatment of nonmelanoma skin cancer.

Authors:  Sadegh Amini; Martha H Viera; Whitney Valins; Brian Berman
Journal:  J Clin Aesthet Dermatol       Date:  2010-06

Review 2.  Interventions for actinic keratoses.

Authors:  Aditya K Gupta; Maryse Paquet; Elmer Villanueva; William Brintnell
Journal:  Cochrane Database Syst Rev       Date:  2012-12-12

Review 3.  Diclofenac/hyaluronic acid.

Authors:  D C Peters; R H Foster
Journal:  Drugs Aging       Date:  1999-04       Impact factor: 3.923

4.  Actinic Keratosis and Cutaneous Squamous Cell Carcinoma.

Authors:  Ralf Gutzmer; Susanne Wiegand; Oliver Kölbl; Kai Wermker; Markus Heppt; Carola Berking
Journal:  Dtsch Arztebl Int       Date:  2019-09-13       Impact factor: 5.594

5.  [Topical therapy of squamous cell carcinoma].

Authors:  U R Hengge
Journal:  Hautarzt       Date:  2007-05       Impact factor: 0.751

6.  Cost-utility of first-line actinic keratosis treatments in Finland.

Authors:  Erkki J Soini; Taru Hallinen; Anna-Leena Sokka; Kari Saarinen
Journal:  Adv Ther       Date:  2015-05-26       Impact factor: 3.845

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.